Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1988
Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cellsR M Hudziak, G D Lewis, M R Shalaby, et al.Journal of Leukocyte Biology|March 1, 1987
Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alphaM R Shalaby, M A Palladino, S E Hirabayashi, et al.Journal of Immunological Methods|April 9, 2001
Expression of single-chain Fv-Fc fusions in Pichia pastorisD B Powers, P Amersdorfer, M Poul, et al.Clinical Immunology and Immunopathology|October 1, 1991
Cytokine-associated tissue injury and lethality in mice: a comparative studyM R Shalaby, J Halgunset, O A Haugen, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|August 8, 2001
Tumor targeting using anti-her2 immunoliposomesJ W Park, D B Kirpotin, K Hong, et al.Proceedings of the National Academy of Sciences of the United States of America|February 28, 1995
Development of anti-p185HER2 immunoliposomes for cancer therapyJ W Park, K Hong, P Carter, et al.Cellular Immunology|November 1, 1987
The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vitroM R Shalaby, J F Krowka, T J Gregory, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1987
Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunityM A Palladino, M R Shalaby, S M Kramer, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 15, 1986
Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytesP M Peters, J R Ortaldo, M R Shalaby, et al.Cancer Biotherapy & Radiopharmaceuticals|April 1, 1996
186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterpartsC E Kotts, F M Su, C Leddy, et al.Pageof 7